<DOC>
	<DOCNO>NCT02145559</DOCNO>
	<brief_summary>Given role mTOR signal probable synergistic activity combine sirolimus metformin patient advance solid tumor , investigator hypothesize : 1 . The combination metformin plus sirolimus result reduction p4EBP1 , p70S6K pAKT sirolimus alone peripheral blood T cell ( PBTC ) . 2 . The combination metformin plus sirolimus result decrease level serum biomarkers include fast insulin , C-peptide , glucose , triglyceride , LDH , IGF-1 , IGF-1R , IGF-BP leptin , increase adiponectin peripheral blood . 3 . Expression active form AMPK , mTOR , PI3K , PTEN loss , AKT , LKB1 , P62 , LC3 , and/or ULK1 tumor tissue ( original pathology ) predictive response combination therapy . This exploratory hypothesis study . 4 . Sirolimus induced toxicity , especially hyperglycemia hypertriglyceridemia , mitigate combine sirolimus metformin . 5 . Metformin plus sirolimus promising anti-cancer activity activity correlate decrease biomarkers . This exploratory hypothesis study .</brief_summary>
	<brief_title>A Pharmacodynamic Study Sirolimus Metformin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Objectives : This descriptive study evaluate pharmacodynamic marker dual sirolimus metformin therapy . Primary Objective : . To compare change pharmacodynamic biomarker p70S6K peripheral blood T cell combination metformin XR sirolimus sirolimus alone . Secondary Objectives : . To compare change pharmacodynamic biomarkers p4EBP1 pAKT peripheral blood T cell combination metformin XR sirolimus sirolimus alone . ii . To assess tolerability combination metformin XR plus sirolimus select dos . iii . To compare fast serum glucose triglyceride sirolimus addition metformin XR . Study Design : This open-label , randomize study eligible patient histologically-confirmed advanced solid tumor start sirolimus ( 3 mg daily ) alone first 7 day ( lead-in period ) ; cycle 1 , day 1-8 . Before start sirolimus investigator obtain previous pathology ( available ) collect blood lymphocyte baseline test biomarkers show study calendar . The pharmacodynamic biomarkers collect cycle 1 , day 8 ass effect sirolimus alone biomarkers . In previous study , effect sirolimus p70S6K observe within 48 hour first dose9 . On day 8 , patient randomize 1:1 metformin XR ( 500 mg daily even meal ) metformin two week ( day 21 ) . On day 15 , patient randomize metformin XR dose increase 1000 mg daily grade ≥ 2 toxicity due metformin XR . Patients develop grade 2 toxicity due metformin maintain metformin XR 500 mg daily rest study , patient develop &gt; grade 2 toxicity take study . A repeat biomarkers evaluation do cycle 1 , day 22 ass effect add metformin pharmacodynamic biomarkers . From day 22 onwards , patient combination sirolimus metformin . Patients initially randomize metformin XR begin take 500 mg daily even meal titrated 1000 mg daily one week , . Each cycle 4 week . CT scan obtain every 2 cycle assess response RECIST version 1.140 . Metformin temporarily hold day CT scan resume 48 hour CT scan . This due increase risk lactic acidosis iodinate contrast agent standard procedure contrast enhance CT scan University Chicago .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically cytologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective . 2 . ECOG performance status 0 1 ( See Appendix B ) . 3 . Age ≥ 18 year . 4 . Nonpregnant , nonlactating woman use adequate contraception . 5 . Ability understand willingness sign inform consent . 6 . Adequate hematologic , renal hepatic function , define follow : Absolute neutrophil count ( ANC ) &gt; l500/μl Platelets &gt; 100,000/μl Total bilirubin &lt; 1.5 x upper limit normal SGOT SGPT &lt; 2.5x upper limit normal patient without liver metastasis SGOT SGPT &lt; 5 x upper limit normal patient liver metastasis . Creatinine &lt; 1.4 mg/dl female &lt; 1.5 mg/dl male . 7 . Prior treatment mTOR inhibitor allow long patient ≥ Grade 3 toxicity attribute mTOR inhibitor prior therapy . 8 . Measurable nonmeasurable disease allow . 9 . Patients take substrate , inhibitor , inducer CYP3A4 ( See Appendix C ) encourage switch alternative drug whenever possible , give potential drugdrug interaction sirolimus . Exclusion Criteria 1 . Prior treatment mTOR inhibitor ( include sirolimus ) allow ; however , patient ≥ grade 3 toxicity mTOR inhibitor exclude . 2 . Fasting glucose &gt; 200 mg/dL fast triglyceride &gt; 300 mg/dL . 3 . Patients chemotherapy immunotherapy within 4 week start study drug , radiotherapy within 14 day start study drug , recover adverse event due agent administer 4 week earlier . 4 . Patients may receive investigational agent concomitant antineoplastic therapy , exception octreotide LAR ( neuroendocrine tumor ) endocrine therapy ( prostate , breast , gynecologic malignancy ) . 5 . Serious underlie medical ( include acute decompensated congestive heart failure ) psychiatric illness would , opinion treat physician , substantially increase risk complication related treatment . Similarly , unstable medical condition , opinion treat physician study investigator , would interfere study objective . 6 . Pregnancy breastfeed . 7 . Major surgery within 4 week . 8 . Concurrent use proton pump inhibitor , limit absorption metformin30,41 . 9 . History lactic acidosis per prior medical record provide patient . 10 . Metabolic acidosis , acute chronic . Acidosis define blood pH &lt; 7.35 . Acidosis suspect serum bicarbonate &lt; 22 mEq/L . In case , venous blood pH would check confirm exclude acidosis . 11 . Participants know uncontrolled diabetes , define hemoglobin A1C &gt; 8 % . 12 . Participants already treatment metformin , except metformin hold 4 week prior start study . 13 . History ongoing alcohol abuse binge drinking . Alcohol abuse define pattern drinking result harm one 's health , interpersonal relationship , ability work . Binge drinking define least one episode consume five unit men four unit woman previous month . One unit alcohol generally say half pint beer , single measure ( shot glass ) spirit small glass table wine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>